secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2022-06-30T23:59:59+00:00
Accession:  0001193125-22-185324
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience receives termination notice from EOC Pharma for FYARRO license in Greater China
--------------------------------------------------------------------------------

- EOC Pharma terminated FYARRO license agreement for Greater China effective June 27, 2022.
- Aadi disputes EOC's allegations of material breach; believes termination is for convenience.
- Aadi had received $14M upfront and $1M milestone; lost potential $257M in milestones and royalties.
- No further payments from EOC expected; Aadi loses exclusive development/commercialization partner for China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522185324/0001193125-22-185324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522185324/d360965d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-185324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer